Literature DB >> 25759214

Boosting antibody developability through rational sequence optimization.

Daniel Seeliger1, Patrick Schulz, Tobias Litzenburger, Julia Spitz, Stefan Hoerer, Michaela Blech, Barbara Enenkel, Joey M Studts, Patrick Garidel, Anne R Karow.   

Abstract

The application of monoclonal antibodies as commercial therapeutics poses substantial demands on stability and properties of an antibody. Therapeutic molecules that exhibit favorable properties increase the success rate in development. However, it is not yet fully understood how the protein sequences of an antibody translates into favorable in vitro molecule properties. In this work, computational design strategies based on heuristic sequence analysis were used to systematically modify an antibody that exhibited a tendency to precipitation in vitro. The resulting series of closely related antibodies showed improved stability as assessed by biophysical methods and long-term stability experiments. As a notable observation, expression levels also improved in comparison with the wild-type candidate. The methods employed to optimize the protein sequences, as well as the biophysical data used to determine the effect on stability under conditions commonly used in the formulation of therapeutic proteins, are described. Together, the experimental and computational data led to consistent conclusions regarding the effect of the introduced mutations. Our approach exemplifies how computational methods can be used to guide antibody optimization for increased stability.

Keywords:  CMC, chemistry, manufacturing and control; DSC, differential scanning calorimetry; HC, heavy chain; LC, light chain; PK, pharmacokinetics; RALS, right angle light scattering; WT, wild-type; biopharmaceuticals; design; developability; mAb, monoclonal antibody; monoclonal antibodies; prediction; protein engineering; stability; thermal stability

Mesh:

Substances:

Year:  2015        PMID: 25759214      PMCID: PMC4622947          DOI: 10.1080/19420862.2015.1017695

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  48 in total

1.  Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations.

Authors:  Raphael Guerois; Jens Erik Nielsen; Luis Serrano
Journal:  J Mol Biol       Date:  2002-07-05       Impact factor: 5.469

2.  ElNemo: a normal mode web server for protein movement analysis and the generation of templates for molecular replacement.

Authors:  Karsten Suhre; Yves-Henri Sanejouand
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

Review 3.  Process economics of industrial monoclonal antibody manufacture.

Authors:  Suzanne S Farid
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-08-08       Impact factor: 3.205

4.  A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties.

Authors:  Thomas Tiller; Ingrid Schuster; Dorothée Deppe; Katja Siegers; Ralf Strohner; Tanja Herrmann; Marion Berenguer; Dominique Poujol; Jennifer Stehle; Yvonne Stark; Martin Heßling; Daniela Daubert; Karin Felderer; Stefan Kaden; Johanna Kölln; Markus Enzelberger; Stefanie Urlinger
Journal:  MAbs       Date:  2013-04-09       Impact factor: 5.857

5.  Structure-based engineering of a monoclonal antibody for improved solubility.

Authors:  Sheng-Jiun Wu; Jinquan Luo; Karyn T O'Neil; James Kang; Eilyn R Lacy; Gabriela Canziani; Audrey Baker; Maggie Huang; Qing Mike Tang; T Shantha Raju; Steven A Jacobs; Alexey Teplyakov; Gary L Gilliland; Yiqing Feng
Journal:  Protein Eng Des Sel       Date:  2010-06-11       Impact factor: 1.650

Review 6.  Therapeutic protein aggregation: mechanisms, design, and control.

Authors:  Christopher J Roberts
Journal:  Trends Biotechnol       Date:  2014-06-04       Impact factor: 19.536

7.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

Review 8.  Scaling and assessment of data quality.

Authors:  Philip Evans
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-12-14

9.  AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides.

Authors:  Oscar Conchillo-Solé; Natalia S de Groot; Francesc X Avilés; Josep Vendrell; Xavier Daura; Salvador Ventura
Journal:  BMC Bioinformatics       Date:  2007-02-27       Impact factor: 3.169

10.  Development of scoring functions for antibody sequence assessment and optimization.

Authors:  Daniel Seeliger
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

View more
  31 in total

Review 1.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

2.  Computer-aided drug design at Boehringer Ingelheim.

Authors:  Ingo Muegge; Andreas Bergner; Jan M Kriegl
Journal:  J Comput Aided Mol Des       Date:  2016-09-20       Impact factor: 3.686

3.  Thermodynamic Unfolding and Aggregation Fingerprints of Monoclonal Antibodies Using Thermal Profiling.

Authors:  Richard Melien; Patrick Garidel; Dariush Hinderberger; Michaela Blech
Journal:  Pharm Res       Date:  2020-04-01       Impact factor: 4.200

4.  Expanding the toolbox for predictive parameters describing antibody stability considering thermodynamic and kinetic determinants.

Authors:  Michaela Blech; Richard Melien; Nuska Tschammer; Beate Presser; Dariush Hinderberger; Patrick Garidel
Journal:  Pharm Res       Date:  2021-12-13       Impact factor: 4.200

5.  Preparation of the luciferase-labeled antibody for improving the detection sensitivity of viral antigen.

Authors:  Ying Tang; Yuchang Li; Sen Zhang; Jing Li; Yi Hu; Wenguang Yang; Yuehong Chen; Chengfeng Qin; Tao Jiang; Xiaoping Kang
Journal:  Virol J       Date:  2022-07-28       Impact factor: 5.913

6.  Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity.

Authors:  Fabian Richter; Kirstin A Zettlitz; Oliver Seifert; Andreas Herrmann; Peter Scheurich; Klaus Pfizenmaier; Roland E Kontermann
Journal:  MAbs       Date:  2018-10-02       Impact factor: 5.857

Review 7.  Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.

Authors:  Rahul Khetan; Robin Curtis; Charlotte M Deane; Johannes Thorling Hadsund; Uddipan Kar; Konrad Krawczyk; Daisuke Kuroda; Sarah A Robinson; Pietro Sormanni; Kouhei Tsumoto; Jim Warwicker; Andrew C R Martin
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

8.  Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.

Authors:  Adriana-Michelle Wolf Pérez; Nikolai Lorenzen; Michele Vendruscolo; Pietro Sormanni
Journal:  Methods Mol Biol       Date:  2022

9.  Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo.

Authors:  Claire L Dobson; Paul W A Devine; Jonathan J Phillips; Daniel R Higazi; Christopher Lloyd; Bojana Popovic; Joanne Arnold; Andrew Buchanan; Arthur Lewis; Joanne Goodman; Christopher F van der Walle; Peter Thornton; Lisa Vinall; David Lowne; Anna Aagaard; Lise-Lotte Olsson; Anna Ridderstad Wollberg; Fraser Welsh; Theodoros K Karamanos; Clare L Pashley; Matthew G Iadanza; Neil A Ranson; Alison E Ashcroft; Alistair D Kippen; Tristan J Vaughan; Sheena E Radford; David C Lowe
Journal:  Sci Rep       Date:  2016-12-20       Impact factor: 4.379

Review 10.  Current progress in innovative engineered antibodies.

Authors:  William R Strohl
Journal:  Protein Cell       Date:  2017-08-18       Impact factor: 14.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.